The incidence of retinopathy of prematurity (ROP) continues to rise due to the improved
survival of very low birth weight infants in developed countries. This epidemic is also fueled …

The population of infants at risk for retinopathy of prematurity (ROP) varies by world region;
in countries with well developed neonatal intensive care services, the highest risk infants are …

Objective To report late reactivation and progression of retinopathy of prematurity (ROP)
after intravitreal bevacizumab monotherapy. Methods Retrospective review of 9 patients (17 …

Retinopathy of prematurity (ROP) is among the most common causes of childhood
blindness. Three phases of ROP epidemics have been observed worldwide since ROP was …

Purpose To compare the structural outcome at 9 months of eyes treated with intravitreal
injection of bevacizumab with fellow eyes treated with conventional laser photoablation in …

Purpose To compare structural outcome at age 4 years of eyes treated with intravitreal
injection of bevacizumab with fellow eyes treated with conventional laser photoablation in …

PURPOSE: To investigate the effectiveness and complications associated with the use of
bevacizumab, an anti–vascular endothelial growth factor agent, in the treatment of …

Retinopathy of prematurity (ROP), a retinal vascular disease of premature infants, continues
to be a major cause of preventable childhood blindness all over the world. The incidence of …

The publication of the BEAT-ROP study of bevacizumab (Avastin) treatment for Zone I and II
retinopathy of prematurity (ROP) has raised hopes that there might now be a simpler …

Purpose To compare structural outcomes, visual function, refraction, and frequency of follow-
up for infants with type 1 retinopathy of prematurity in zone I or zone II posterior treated with …